Alternating hemiplegia of childhood is a rare and complex neurological disorder that brings unique challenges to affected children and their families. Understanding the available treatment options — from proven medications to emerging therapies being tested in clinical trials — can help families navigate the path toward better symptom management and improved quality of life.

Finding Hope in Treatment: Managing a Complex Neurological Condition

When a child receives a diagnosis of alternating hemiplegia of childhood, families face a journey filled with uncertainty. This rare disorder requires careful, lifelong management with the primary goal of reducing the frequency and severity of paralysis episodes while supporting the child’s overall development. Treatment approaches focus on controlling symptoms, preventing complications, and helping children reach their fullest potential despite the challenges the condition presents.^[1]

The treatment landscape for alternating hemiplegia of childhood depends heavily on each child’s unique presentation. Because the disorder affects children differently — some may experience frequent, severe episodes while others have milder symptoms — doctors must tailor treatment plans to individual needs. Medical teams consider factors such as the child’s age, the frequency and severity of paralysis episodes, the presence of other complications like epilepsy, and the child’s developmental progress when designing a care strategy.^[2]

Currently, there is no cure for alternating hemiplegia of childhood, but medical science has identified treatments that can make a meaningful difference. Beyond medication, comprehensive care includes avoiding known triggers, managing related conditions, and providing multidisciplinary support. Research continues to advance our understanding of this disorder, with scientists exploring new therapeutic approaches that may one day transform how we treat this challenging condition.^[3]

Standard Medical Treatment: Established Approaches to Symptom Control

The cornerstone of standard treatment for alternating hemiplegia of childhood centers on a medication called flunarizine, which is a type of drug known as a calcium channel blocker. This medication works by blocking certain channels in nerve cells that control the movement of calcium, which may help reduce the abnormal electrical activity in the brain that triggers paralysis episodes. While flunarizine is not approved by the Food and Drug Administration in the United States, it has been used widely in other countries and remains the most commonly prescribed preventive treatment for this condition.^[10]

Studies and clinical experience suggest that flunarizine can reduce the frequency, duration, and severity of hemiplegic attacks in up to 80% of patients with alternating hemiplegia of childhood. However, the medication does not work equally well for everyone, and some children may experience only modest improvement. Doctors typically prescribe flunarizine as a daily medication that must be taken consistently, even when the child is feeling well, to maintain its protective effect. The goal is prevention rather than treatment of active episodes.^[12]

When paralysis episodes do occur, doctors may use medications called benzodiazepines to help manage the acute attack. These medications have a calming effect on the nervous system and can help relax muscles during episodes of painful stiffness or dystonia. Benzodiazepines can be given in several forms — by mouth, rectally, or through nasal administration — depending on the child’s condition during the episode. Because sleep relieves symptoms in alternating hemiplegia of childhood, some doctors also prescribe sleep-inducing medications such as chloral hydrate or phenobarbital to help end an active episode more quickly.^[10]

Other medications have been tried with varying degrees of success in different patients. Topiramate, an antiepileptic medication, has shown some benefit in reducing attack frequency and severity in certain children. Some doctors have also tried medications including amantadine, memantine, aripiprazole, acetazolamide, and dextromethorphan, though evidence for these treatments comes mainly from individual case reports rather than large studies. The ketogenic diet — a high-fat, low-carbohydrate eating plan originally developed for epilepsy — has also been explored as a potential treatment option, though more research is needed to understand its effectiveness.^[10]

For children who develop epilepsy alongside their alternating hemiplegia — which occurs in about half of all cases — standard antiepileptic medications are prescribed to control seizures. However, doctors must be careful to distinguish true epileptic seizures from the non-epileptic episodes that are part of alternating hemiplegia itself, as treating non-epileptic episodes with seizure medications may not be helpful and could cause unnecessary side effects. Medications commonly used include carbamazepine, barbiturates, and valproic acid, depending on the type of seizures present.^[2]

Managing the behavioral and psychiatric symptoms that often accompany alternating hemiplegia of childhood is another important aspect of treatment. Many children develop attention-deficit/hyperactivity disorder, aggressive behaviors, or mood disturbances, particularly as they enter later childhood and adolescence. Doctors may prescribe mood-stabilizing medications or antipsychotic agents when these symptoms significantly impact the child’s quality of life or ability to participate in daily activities.^[8]

Treatment is typically lifelong, with medication dosages adjusted as children grow and their needs change. Regular follow-up appointments with a neurologist are essential to monitor the child’s response to treatment, manage side effects, and adjust the care plan as needed. Potential side effects of flunarizine can include drowsiness, weight gain, and in rare cases, movement disorders similar to Parkinson’s disease. Benzodiazepines may cause sedation, and with long-term use, the body can develop tolerance or dependence. Each medication carries its own risk profile, which doctors must weigh against potential benefits for each individual child.^[6]

Innovative Approaches in Clinical Trials: Testing Tomorrow’s Treatments

Research into alternating hemiplegia of childhood has accelerated since scientists discovered that mutations in the ATP1A3 gene cause approximately 80% of cases. This gene provides instructions for making part of a protein pump called Na+/K+ ATPase, which moves sodium and potassium ions across nerve cell membranes. When this pump doesn’t work properly due to genetic mutations, nerve cells in the brain cannot function normally, leading to the symptoms of alternating hemiplegia of childhood. Understanding this genetic basis has opened new doors for developing targeted therapies that address the root cause of the disorder rather than just managing symptoms.^[1]

One promising area of research involves exploring medications that can improve the function of the defective Na+/K+ ATPase pump or work around its malfunction. Scientists are investigating various compounds that might restore more normal ion transport in nerve cells, though these approaches are still largely in early research phases. The challenge lies in finding treatments that can reach the brain, target the specific problem without disrupting normal nerve cell function elsewhere in the body, and be safe for long-term use in children.^[6]

Researchers are also studying how the ATP1A3 mutations affect different types of brain cells. The Na+/K+ ATPase protein is particularly abundant in certain inhibitory neurons that use a chemical messenger called GABA. When these neurons don’t work properly, it can lead to excessive excitability in brain circuits, potentially contributing to both the paralysis episodes and the development of epilepsy in affected children. Clinical trials are exploring whether medications that enhance GABA function or reduce excessive neuronal excitability might provide benefits for children with alternating hemiplegia of childhood.^[6]

Another research direction focuses on ion channels that interact with the faulty Na+/K+ ATPase pump. Scientists have found that N-type voltage-gated calcium channels and ATP-sensitive potassium channels may play important roles in the disorder. These channels help control nerve cell activity, and when the Na+/K+ ATPase isn’t working correctly, the abnormal flow of ions through these channels might contribute to symptoms. Medications that modulate these channels are being studied as potential treatments. This may explain why flunarizine, which affects calcium channels, provides benefit to some patients — though its exact mechanism of action in alternating hemiplegia of childhood is not fully understood.^[6]

A medication called sodium oxybate has attracted attention as a potential treatment option. This drug is normally used to treat narcolepsy, but researchers have become interested in it for alternating hemiplegia of childhood because of its effects on sleep and brain chemistry. Some preliminary observations suggest that sodium oxybate might help reduce the frequency or severity of episodes in certain patients, though formal clinical trials are needed to properly evaluate its safety and effectiveness in this population.^[10]

Researchers are also investigating whether compounds that support cellular energy production might help. A substance called triheptanoin — a specially formulated type of fat that can provide energy to cells in a different way than regular dietary fats — is being studied for its potential to improve cellular function in nerve cells affected by ATP1A3 mutations. Other approaches being explored include coenzyme Q supplementation and oral ATP administration, based on the theory that supporting cellular energy metabolism might help compensate for the defective ion pump.^[10]

Some clinical trials are exploring the use of implanted devices, such as vagus nerve stimulators, which are already approved for treating epilepsy. These devices deliver mild electrical stimulation to a nerve in the neck that connects to the brain, potentially helping to stabilize abnormal electrical activity. While primarily used for seizure control, researchers are interested in whether such devices might also reduce the frequency of hemiplegic episodes, though evidence remains limited.^[10]

The most exciting frontier in research involves gene therapy approaches that could potentially correct or compensate for the faulty ATP1A3 gene. Scientists are exploring whether it might be possible to deliver a healthy copy of the gene to brain cells, or to use newer gene-editing technologies to repair the mutation directly. While these approaches remain in early research stages and face significant technical challenges — particularly the difficulty of delivering genetic treatments safely to the brain — they represent a potential path toward addressing the fundamental cause of the disorder rather than just managing symptoms. These cutting-edge therapies are being developed and tested in laboratory models before they can move to human trials.^[2]

Research centers with specialized expertise in alternating hemiplegia of childhood, such as Duke University in the United States and several centers in Europe, are actively conducting clinical studies and offering advanced genetic testing and counseling services. Many of these centers welcome patients into research registries that help scientists better understand how the disorder progresses over time and how different patients respond to various treatments. Participation in such registries, even without joining a drug trial, contributes valuable information that helps advance the field and may lead to better treatments in the future.^[3]

Most Common Treatment Methods

• Preventive Medication with Flunarizine
  • Daily calcium channel blocker medication to reduce frequency, severity, and duration of paralysis episodes
  • Reported to help up to 80% of patients with alternating hemiplegia of childhood
  • Not FDA approved in the United States but widely used internationally
  • Must be taken consistently for preventive effect; works by blocking voltage-dependent calcium channels in nerve cells
• Acute Episode Management
  • Benzodiazepines administered orally, rectally, or nasally during active paralysis or dystonic episodes
  • Sleep-inducing medications such as chloral hydrate or phenobarbital to help end episodes through sleep
  • Symptoms typically resolve completely during sleep, making sleep induction a key management strategy
• Antiepileptic Medications
  • Standard seizure medications for the approximately 50% of patients who develop epilepsy
  • Common medications include carbamazepine, barbiturates, and valproic acid
  • Topiramate has shown some benefit in reducing attack frequency in addition to seizure control
  • Careful distinction needed between true epileptic seizures and non-epileptic episodes of alternating hemiplegia
• Behavioral and Psychiatric Medications
  • Mood stabilizers and antipsychotic agents for behavioral issues, aggression, and ADHD symptoms
  • Aripiprazole and other medications to manage psychiatric complications that emerge in later childhood and adolescence
• Dietary Interventions
  • Ketogenic diet (high-fat, low-carbohydrate) explored as potential treatment approach
  • Triheptanoin supplementation being studied in research settings
  • Coenzyme Q and oral ATP supplements tried with varying success
• Other Medication Approaches
  • Amantadine, memantine, acetazolamide, and dextromethorphan tried in individual cases with variable results
  • Sodium oxybate being explored for potential episode reduction
  • Various medications targeting ion channels and cellular energy production under investigation
• Device-Based Therapies
  • Vagus nerve stimulator implantation explored primarily for epilepsy control but potentially affecting episode frequency
• Multidisciplinary Support
  • Physical therapy, occupational therapy, and speech therapy to address developmental delays and motor impairments
  • Neuropsychological support for cognitive and learning challenges
  • Dietary counseling for feeding difficulties and maintaining proper nutrition
  • Specialized educational support and behavioral interventions